Centessa Gets FDA Orphan Designation for SerpinPC in Hemophilia B
14 September 2022 - 11:44PM
Dow Jones News
By Colin Kellaher
Centessa Pharmaceuticals PLC on Wednesday said the U.S. Food and
Drug Administration granted orphan-drug designation to its lead
candidate SerpinPC for the treatment of the hereditary bleeding
disorder hemophilia B.
The U.K.-based clinical-stage pharmaceutical company said it
plans to begin registrational studies of SerpinPC in the fourth
quarter.
The FDA's orphan-drug program gives special status to drugs and
biologics for diseases and disorders that affect fewer than 200,000
people in the U.S. and provides for an extended marketing
exclusivity period against competition.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 14, 2022 09:29 ET (13:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Aug 2023 to Aug 2024